Articles

Poll

Podcasts

Slideshows

Videos

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Our top 5 headlines featured key FDA moves in nephrology and ophthalmology, from new approvals to trial terminations and priority reviews.

The HCPFive: Top News for Healthcare Providers from the Week of 03/30

Chronic hypoparathyroidism requires holistic management addressing more than just calcium normalization to achieve optimal patient outcomes.

Beyond Calcium: A Holistic Approach to Optimizing Outcomes for Patients with Hypoparathyroidism

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

FDA Approves Palopegteriparatide for Hypoparathyroidism

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

Endocrinology Month in Review: July 2024

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

Testosterone Ineffective in Preventing Diabetes in Men with Hypogonadism 

Fracture occurrences were numerically higher among men who received testosterone than placebo across a subtrial of the phase 4 TRAVERSE trial. 

Testosterone Treatment Does Not Reduce Fracture Risk in Men with Hypogonadism

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

TRAVERSE Trial: No Increased Cardiovascular Risk with Testosterone Replacement Therapy 

Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.

FDA Issues Complete Response Letter for TransCon PTH in Hypoparathyroidism

In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.

Hormone Therapy Linked to Positive Changes in Appearance Congruence, Mental Health for Transgender and Nonbinary Youth

Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.

Hormonal Disorders